A portable-medication-test-card startup a day keeps the FOMO away.
Startup of the Year | Daily Dealflow | Powered by ESTABLISHED

Startup of the Year: Daily Dealflow 

Startup of the Year discovers and supports the
most promising and innovative startups from around the world.
 
#DailyDealflow newsletter delivers one seed-stage startup a day, every work day
and is presented by Silicon Valley Bank.
Veripad logo

Veripad

Veripad's portable chemical test card and a companion mobile application make it easier than ever to detect counterfeit and falsified medicines.
Veripad is a U.S. based health IT company working to prevent the spread of counterfeit and falsified medicines globally by offering an affordable and convenient technology to chemically test the quality of medicines. Our innovative technology uses a portable chemical test card and a companion mobile application to determine the quality of suspicious medicines in minutes. By essentially creating a lab in your pocket, Veripad has made it easier than ever to detect counterfeit and falsified medicines in any environment.
Twitter
Facebook
Instagram
LinkedIn

📍 Location

New York, NY

⚙️ Product Stage

Beta—Public

🏭 Industries

Health and Wellness, Medical Devices, Pharmaceuticals

🤑 Fundraising Status

Prefer not to say

📈 Last Funding Stage

Angel

💸 Total Funding to Date

$50,000

Big Wins

We currently have two pilots running. One with the Kenyan Government and one with Americares, a multinational NGO. Our technology has been used over 5000 times by partners in 7 countries around the world. We have also obtained a sponsorship by Merck, KGaA, a multinational pharmaceutical company. We have secured two new B2B customers who have ordered our technology for use in Q1 2018.

Competitive Advantage

Veripad's core innovation is a test card pre-loaded with chemical reagents that react with various medicines to identify their components and the companion mobile application that quickly interprets the results for the user. It is disruptively affordable and easy-to-use, making it possible to collect data from many more locations, and with much larger sample sizes. This allows for a more thorough understanding of where counterfeit medicines originate and travel. With this information, not only does the user now know if their medicine is authentic, everyone in their community can benefit and be protected. As we grow and more users test medicines, the data can help pharmaceutical companies, government regulatory agencies, and NGOs create more impactful policies and legislation. The aggregated data will also be used to create a comprehensive predictive analytics platform which will help ensure the security of the global supply chain through real-time monitoring of drug quality.
 

Watch the video

Download the deck

Contact the Founder:

Bishoy Ghobryal

[email protected]

Subscribe
Submit your Startup
Past Issues
The Daily Dealflow is made possible thanks to the support of our amazing partners.
svb > Silicon Valley Bank
Silicon Valley Bank and its extensive team of early stage startup experts are supporters of startup communities everywhere. Click here to learn more.
Do you travel for business? American Airlines® has a free, special offer for our friends – companies who enroll in their Business Extra program can earn up to 600 bonus Business Extra points. The program allows your travelers to earn their AAdvantage® miles while collectively earning Business Extra points for the business.
ESTABLISHED
Startup of the Year is powered by Established, a consultancy focused on helping organizations with their innovation, startup, and communication strategies.
 
Created by the talent responsible for building the Tech.Co brand (acquired by an international publishing company), we're leveraging decades of experience to help our collaborators further (or create) their brand & accomplish their most important goals.
Facebook Twitter Instagram LinkedIn
Established, LLC is not a broker-dealer and cannot provide assurances and makes no representations or warranties as to the timing or price terms for any purchase or sale of early-stage company equity. Nothing contained in this email constitutes investment, legal, tax or other advice. No information or statements contained in this email should be relied upon in making an investment or different decision. You should review all risks and consult all applicable professionals when making any investment decisions. Information and statements contained within this email and any attachments are solely for informational purposes and does not constitute an offer to sell or a solicitation to buy any securities.

[Sender_Name]

[Sender_Address], [Sender_City], [Sender_State] [Sender_Zip]

Unsubscribe - Unsubscribe Preferences